|
www.ncbi.nlm.nih.gov/pubmed/18049336
|
A phase I/II trial was undertaken to determine the maximum tolerated dose of polyethylene glycol interferon-alpha-2b (PEG-IFN) with interleukin-2 (IL-2), and to ...
|
|
www.ncbi.nlm.nih.gov/pubmed/1804310
|
A polyethylene glycol-modified form of recombinant human IL-2 (PEG-IL-2) was ... This PEG-IL-2 was demonstrated to retain the in vitro ability to support T cell ...
|
|
www.cancer.gov/drugdictionary?cdrid=39577
|
A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural ...
|
|
annonc.oxfordjournals.org/content/5/10/957.short
|
Conclusion Intratumoral injection of PEG-IL-2 in patients with HNSCC is feasible. This treatment appears beneficial for highly selected patients. The objective ...
|
|
clinicaltrials.gov/ct2/show/NCT00015652
|
Apr 26, 2001 ... PEG-IFN alfa-2b is approved by the FDA for use in treating HCV but has not yet been approved for use with RBV. This study also will use IL-2, ...
|
|
|
|
www.ualberta.ca/~csps/JPPS3(1)/R.Mehvar/Glycol.htm
|
Interleukin-2 (IL-2): Both animal and clinical studies have been conducted using PEG conjugates of IL-2. Earlier studies in animals (58, 59) and humans (60) ...
|
|
www.jstor.org/stable/30132610
|
PEG-IL-2 was administered by intravenous infusions every. 2 weeks ... after four doses of PEG-IL-2, escalating to 1600 gIg/m2 weekly for an additional 2 months.
|
|
onlinelibrary.wiley.com/doi/10.1002/ijc.2910510524/pdf
|
kin-2 (PEG-IL-2) represents a cytokine with prolonged circula- tory half-life and ... We studied whether PEG-IL-2 would also be advantageous in locoregional ...
|
|
www.jbc.org/content/263/29/15064.full.pdf
|
7 To whom all correspondence should be addressed. The abbreviations used are: PEG, monmethoxy polyethylene glycol; rIL-2, recombinant interleukin-2; POG, ...
|
